Analysis of the effectiveness of platinib (Pujihua) in patients with RET fusion mutations

Pralsetinib is a selective RET tyrosine kinase inhibitor mainly used to treat patients with RET fusion or mutation-driven advanced solid tumors, including non-small cell lung cancer and medullary thyroid cancer. RETGene fusion accounts for a relatively small proportion of some patients with non-small cell lung cancer (NSCLC), but it plays a key role in tumor growth and progression. Platinib inhibits tumor cell proliferation and survival by targeting the RET signaling pathway, thereby achieving effective control of patients with RET fusion mutations.

In clinical trials, platinib demonstrated a high objective response rate (ORR) in RET fusion-positive patients. For patients with advanced NSCLC who have previously received chemotherapy, studies have shown that the overall objective response rate of platinib can reach more than 60%, with both complete responses and partial responses reported. This effect is more obvious in patients who have not received RET inhibitor treatment before, indicating that platinib has significant anti-tumor activity in the initial targeted therapy stage.

In addition, the efficacy of platinib in different subgroups of patients is relatively stable. Regardless of whether the patients had brain metastases or previous treatment history, their ORR and disease control rate showed good consistency. This shows that platinib can effectively penetrate the blood-brain barrier and also has a certain effect on central nervous system metastasis. At the same time, it can still maintain a high response rate in the context of multi-line treatment, providing an important treatment option for patients with RET fusion mutations.

In terms of maintenance time of efficacy, platinib also showed good tolerability and long-term control capabilities. Most patients still maintain stable disease or sustained remission after more than 6 months of treatment, and some patients can have a remission period of more than one year. Combined with its good oral accessibility and manageable safety profile, platinib provides an efficient, safe and convenient targeted treatment option for patients with RET fusion mutations, showing significant application value in clinical practice.

Reference materials:https://www.drugs.com/